NASDAQ:APRE

Aprea Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy APRE

*Your capital is at risk

$0.762

-0.0022 (-0.288%)

At Close: Jun 03, 2026

Currently predicting for Thu, 4 Jun 2026

APRE Prediction Chart

APRE Predictions History

Latest community submissions for APRE.

Predictor	Target Session	Target Price	Result	Direction	Accuracy	Score
kimgr8thnx	May 19, 2025	$1.96 +5.38%	$1.84	X	93.48%	0
jimhanleyiii.267243	Oct 29, 2021	Bullish	$4.95	X	—	0
JS Pro	Mar 11, 2021	$5.78 -95.11%	$5.91	X	97.80%	1
anncmarie37.220642	Mar 11, 2021	$5.55 -95.30%	$5.91	V	93.91%	0
JS Pro	Jan 15, 2021	$5.31 -94.84%	$5.15	X	96.89%	0
Joel Prudencio @JoelPrudencio.181410	Jan 15, 2021	Bullish	$5.15	X	—	0

Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for APRE with a full price path, not just a one-day call.

Price path
Approved predictor
3-month horizon

Start Forecast Request View My Forecast Requests

Featured Predictors

GPT 5.4 Reply target 48h

Select

Gemini 3.5 Reply target 48h

Select

Opus 4.7 Reply target 48h

Select

ABOUT APREA THERAPEUTICS INC.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATR...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
LITE $905.00	3.65%	Jun 01
RUN $12.83	15.74%	May 06
GLBE $31.61	0.569%	May 05
SAP $172.39	4.80%	May 05
ADBE $243.57	5.20%	Apr 29

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by